SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Amarin Corporation plc (AMRN) News

Follow Amarin Corporation plc (AMRN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol AMRN Asset equity Sector Markets 90 days 9 Last 10.6 Updated Oct 29, 2026, 08:22 AM UTC Open live news feed Open AMRN chart & news
M Amarin Reports Fiscal Q3 Net Loss Amarin reported a fiscal 2026 third-quarter net loss attributable to shareholders, up 52.32% year over year. Basic EPS was negative. EQUITY | Oct 29, 2026, 08:22 AM UTC L Amarin Reports Results for Quarter Ended September 30 Amarin reported results for the quarter ended September 30. EARNINGS | Oct 28, 2026, 02:11 PM UTC M Amarin Q3 Revenue Falls 20% on US Pricing Pressure EQUITY | Oct 28, 2026, 11:23 AM UTC M Amarin reports Q3 non-GAAP earnings of $0.08 per ADS EQUITY | Oct 28, 2026, 11:20 AM UTC M Amarin Returns to Profit in Q3 2026 as Net Sales Fall Amarin returned to profitability in Q3 2026, while net sales declined year over year. EARNINGS | Oct 28, 2026, 11:15 AM UTC M Amarin Reports Q3 2026 Net Income of $245,000 Amarin swung to net income of $245,000 in Q3 2026, compared with a loss a year earlier. EARNINGS | Oct 28, 2026, 11:15 AM UTC M Amarin Reports Third-Quarter Revenue of $39.6 Million EQUITY | Oct 28, 2026, 11:13 AM UTC L AMRN presents REDUCE-IT legacy analysis at ESC 2026 AMRN presented new REDUCE-IT legacy analysis at the European Society of Cardiology (ESC) Congress 2026 on persistent cardiovascular benefit after icosapent ethyl cessation in adherent patients. GEOPOLITICS | Aug 28, 2026, 12:15 PM UTC H AMRN - New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026 - Cli AMRN - New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026 GEOPOLITICS | Aug 24, 2026, 12:15 PM UTC L JPMorgan initiates AMRN at Underweight with $13.00 target JPMorgan initiates AMRN with an Underweight rating and a $13.00 price target. EQUITY | Aug 21, 2026, 11:58 AM UTC L AMRN - Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy AMRN - Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence EARNINGS | Jul 29, 2026, 11:01 AM UTC H serial disappointer risk (missed last qtr) in EPS reporters tonight and tomorrow morning - CGAU, OI, FCF, RCKY, RPT, APAM, GEHC, PB, VFC, OG serial disappointer risk (missed last qtr) in EPS reporters tonight and tomorrow morning - CGAU, OI, FCF, RCKY, RPT, APAM, GEHC, PB, VFC, OGE, SITE, ARCC, BTU, STRA, MNRO, MCHB, RDWR, SHEN, AMRN EARNINGS | Jul 28, 2026, 04:09 PM UTC L Amarin Highlights Recent FDA Approval Of Injectable Apolipoprotein C-III Therapies For Treatment Of Severe Hypertriglyceridemia, Defined As Amarin Corporation plc (NASDAQ: AMRN ), a company committed to advancing the science of cardiovascular disease worldwide, applauds the recent FDA approval of injectable apolipoprotein C-III (APOC3) therapies for the trea REGULATION | Jun 30, 2026, 08:18 PM UTC